Product Information

MOUNJARO 12.5 MG/0.5 ML PEN is a brand product labeled by Eli Lilly and Company, priced at $538.4791 per ML under NDC 00002146080. Its NADAC has been published 196 times since Nov 23, 2022.

FDA first approved this application on May 13, 2022.

MOUNJARO 12.5 MG/0.5 ML PEN

tirzepatide
$538.4791per ML

Strength

12.5 mg/.5mL

NDC

00002146080

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

TIRZEPATIDE

Approval Type

New Drug (NDA)

FDA Application

NDA215866

FDA Approved

5/13/2022

On Market Since

5/13/2022

Pharmacological Classes

G-Protein-linked Receptor Interactions
GLP-1 Receptor Agonist
Glucagon-like Peptide-1 (GLP-1) Agonists
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

Price Statistics

The NADAC for MOUNJARO 12.5 MG/0.5 ML PEN has been published 196 times since Nov 23, 2022, and over the history we have for it it has risen 15.0%. The table below summarizes its recorded NADAC range and movement.

Current price$538.4791 per ML
All-time high$538.5770 (May 13, 2026)
All-time low$468.2471 (Nov 23, 2022)
52-week high$538.5770
52-week low$522.8024
Median price$515.5422
Average price$513.1923
Largest weekly change+5.0% (Jan 11, 2023)
Weeks tracked196
Tracking sinceNov 23, 2022

Price History

1W

+0.0%

1M

+0.0%

3M

+0.0%

6M

-0.0%

1Y

+3.0%

3Y

+9.3%

5Y

N/A

All

+15.0%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 2%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of MOUNJARO 12.5 MG/0.5 ML PEN?

The current National Average Drug Acquisition Cost (NADAC) for MOUNJARO 12.5 MG/0.5 ML PEN, manufactured by Eli Lilly and Company, is $538.4791 per ML (NDC 00002146080), effective Aug 19, 2026.

How has the price of MOUNJARO 12.5 MG/0.5 ML PEN changed over time?

Over the history we have for it, the NADAC for MOUNJARO 12.5 MG/0.5 ML PEN has risen 15.0%. It has been tracked across 196 weekly CMS publications since Nov 23, 2022.

What are the highest and lowest recorded NADAC prices for MOUNJARO 12.5 MG/0.5 ML PEN?

Since Nov 23, 2022, the NADAC for MOUNJARO 12.5 MG/0.5 ML PEN has ranged from a low of $468.2471 (Nov 23, 2022) to a high of $538.5770 (May 13, 2026), with a median of $515.5422 per ML.

Are there cheaper alternatives to MOUNJARO 12.5 MG/0.5 ML PEN?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZEPBOUND 12.5 MG/0.5 ML PEN, is $525.7711 per ML — about 2% below MOUNJARO 12.5 MG/0.5 ML PEN.

Who manufactures MOUNJARO 12.5 MG/0.5 ML PEN?

MOUNJARO 12.5 MG/0.5 ML PEN (NDC 00002146080) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.